Cargando…
A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications
BACKGROUND: Allogeneic mesenchymal stromal cells (MSCs) have been used extensively in various clinical trials. Nevertheless, there are concerns about their efficacy, attributed mainly to the heterogeneity of the applied populations. Therefore, producing a consistent population of MSCs is crucial to...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852915/ https://www.ncbi.nlm.nih.gov/pubmed/35175538 http://dx.doi.org/10.1007/s12015-022-10351-x |
_version_ | 1784653128164966400 |
---|---|
author | Pakzad, Mohammad Hassani, Seyedeh Nafiseh Abbasi, Fatemeh Hajizadeh-Saffar, Ensiyeh Taghiyar, Leila Fallah, Nasrin Haghparast, Newsha Samadian, Azam Ganjibakhsh, Meysam Dominici, Massimo Baharvand, Hossein |
author_facet | Pakzad, Mohammad Hassani, Seyedeh Nafiseh Abbasi, Fatemeh Hajizadeh-Saffar, Ensiyeh Taghiyar, Leila Fallah, Nasrin Haghparast, Newsha Samadian, Azam Ganjibakhsh, Meysam Dominici, Massimo Baharvand, Hossein |
author_sort | Pakzad, Mohammad |
collection | PubMed |
description | BACKGROUND: Allogeneic mesenchymal stromal cells (MSCs) have been used extensively in various clinical trials. Nevertheless, there are concerns about their efficacy, attributed mainly to the heterogeneity of the applied populations. Therefore, producing a consistent population of MSCs is crucial to improve their therapeutic efficacy. This study presents a good manufacturing practice (GMP)-compatible and cost-effective protocol for manufacturing, banking, and lot-release of a homogeneous population of human bone marrow-derived clonal MSCs (cMSCs). METHODS: Here, cMSCs were isolated based on the subfractionation culturing method. Afterward, isolated clones that could reproduce up to passage three were stored as the seed stock. To select proliferative clones, we used an innovative, cost-effective screening strategy based on lengthy serial passaging. Finally, the selected clones re-cultured from the seed stock to establish the following four-tired cell banking system: initial, master, working, and end of product cell banks (ICB, MCB, WCB, and EoPCB). RESULTS: Through a rigorous screening strategy, three clones were selected from a total of 21 clones that were stored during the clonal isolation process. The selected clones met the identity, quality, and safety assessments criteria. The validated clones were stored in the four-tiered cell bank system under GMP conditions, and certificates of analysis were provided for the three-individual ready-to-release batches. Finally, a stability study validated the EoPCB, release, and transport process of the frozen final products. CONCLUSION: Collectively, this study presents a technical and translational overview of a GMP-compatible cMSCs manufacturing technology that could lead to the development of similar products for potential therapeutic applications. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12015-022-10351-x. |
format | Online Article Text |
id | pubmed-8852915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-88529152022-02-18 A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications Pakzad, Mohammad Hassani, Seyedeh Nafiseh Abbasi, Fatemeh Hajizadeh-Saffar, Ensiyeh Taghiyar, Leila Fallah, Nasrin Haghparast, Newsha Samadian, Azam Ganjibakhsh, Meysam Dominici, Massimo Baharvand, Hossein Stem Cell Rev Rep Article BACKGROUND: Allogeneic mesenchymal stromal cells (MSCs) have been used extensively in various clinical trials. Nevertheless, there are concerns about their efficacy, attributed mainly to the heterogeneity of the applied populations. Therefore, producing a consistent population of MSCs is crucial to improve their therapeutic efficacy. This study presents a good manufacturing practice (GMP)-compatible and cost-effective protocol for manufacturing, banking, and lot-release of a homogeneous population of human bone marrow-derived clonal MSCs (cMSCs). METHODS: Here, cMSCs were isolated based on the subfractionation culturing method. Afterward, isolated clones that could reproduce up to passage three were stored as the seed stock. To select proliferative clones, we used an innovative, cost-effective screening strategy based on lengthy serial passaging. Finally, the selected clones re-cultured from the seed stock to establish the following four-tired cell banking system: initial, master, working, and end of product cell banks (ICB, MCB, WCB, and EoPCB). RESULTS: Through a rigorous screening strategy, three clones were selected from a total of 21 clones that were stored during the clonal isolation process. The selected clones met the identity, quality, and safety assessments criteria. The validated clones were stored in the four-tiered cell bank system under GMP conditions, and certificates of analysis were provided for the three-individual ready-to-release batches. Finally, a stability study validated the EoPCB, release, and transport process of the frozen final products. CONCLUSION: Collectively, this study presents a technical and translational overview of a GMP-compatible cMSCs manufacturing technology that could lead to the development of similar products for potential therapeutic applications. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12015-022-10351-x. Springer US 2022-02-17 2022 /pmc/articles/PMC8852915/ /pubmed/35175538 http://dx.doi.org/10.1007/s12015-022-10351-x Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Pakzad, Mohammad Hassani, Seyedeh Nafiseh Abbasi, Fatemeh Hajizadeh-Saffar, Ensiyeh Taghiyar, Leila Fallah, Nasrin Haghparast, Newsha Samadian, Azam Ganjibakhsh, Meysam Dominici, Massimo Baharvand, Hossein A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications |
title | A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications |
title_full | A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications |
title_fullStr | A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications |
title_full_unstemmed | A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications |
title_short | A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications |
title_sort | roadmap for the production of a gmp-compatible cell bank of allogeneic bone marrow-derived clonal mesenchymal stromal cells for cell therapy applications |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852915/ https://www.ncbi.nlm.nih.gov/pubmed/35175538 http://dx.doi.org/10.1007/s12015-022-10351-x |
work_keys_str_mv | AT pakzadmohammad aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT hassaniseyedehnafiseh aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT abbasifatemeh aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT hajizadehsaffarensiyeh aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT taghiyarleila aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT fallahnasrin aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT haghparastnewsha aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT samadianazam aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT ganjibakhshmeysam aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT dominicimassimo aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT baharvandhossein aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT pakzadmohammad roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT hassaniseyedehnafiseh roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT abbasifatemeh roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT hajizadehsaffarensiyeh roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT taghiyarleila roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT fallahnasrin roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT haghparastnewsha roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT samadianazam roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT ganjibakhshmeysam roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT dominicimassimo roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications AT baharvandhossein roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications |